ArticleTransfusion2025
Impact of platelet transfusions on plasma proteomes in controlled endotoxemia and in hemato-oncological patients.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hemostatic and platelet proteins are associated with bleeding grade and time to major bleed in hemato-oncological patients.Blood vessels, thrombosis & hemostasis · 2026Article
- Impact of platelet transfusions on plasma proteomes in controlled endotoxemia and in hemato-oncological patients.Transfusion · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundInflammation is a hallmark of patients that receive platelet transfusions, including critically ill and hemato-oncological patients. Platelet transfusions have been suggested to exacerbate inflammatory conditions, resulting in transfusion-related complications. Here, we used plasma proteomics to study the impact of platelet transfusions under inflammatory conditions.
methodsPlasma proteomics was performed in samples from two studies: (1) 252 samples from healthy volunteers from 36 cases divided into groups (n = 6) with and without controlled endotoxemia, each with different platelet products, and (2) 54 samples from 27 transfusion events in hemato-oncological patients (n = 14). Both studies had samples pre- and post-transfusions.
resultsControlled endotoxemia elicited a shared inflammatory response across all healthy volunteers. This response was characterized by increased abundance of two kinetically distinct protein clusters, an initial cluster associated with degranulation and inflammation (i.e., S100A9 and MMP9) followed by a cluster of acute-phase proteins (i.e., SAA and CRP). Autologous platelet transfusions in healthy individuals did not induce transfusion-specific changes in plasma protein levels, nor did they exacerbate the effect of controlled endotoxemia. In hemato-oncological patients, we found a transfusion-specific response restricted to alterations in platelet basic protein (PPBP) levels. No additional changes in plasma protein profiles associated with inflammation or dysregulated processes were observed following platelet transfusions. DISCUSSION: Platelet transfusions did not induce specific quantitative changes in plasma protein levels in healthy volunteers. Nonetheless, they were associated with increased levels of PPBP in hemato-oncological patients. In general, no evidence of inflammation or other dysregulated processes was observed following platelet transfusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.